Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Pediatric Endocrinology and Metabolism

Editor-in-Chief: Kiess, Wieland

Ed. by Bereket, Abdullah / Darendeliler, Feyza / Dattani, Mehul / Gustafsson, Jan / Luo, Fei Hong / Mericq, Veronica / Toppari, Jorma


IMPACT FACTOR 2018: 1.239

CiteScore 2018: 1.22

SCImago Journal Rank (SJR) 2018: 0.507
Source Normalized Impact per Paper (SNIP) 2018: 0.562

Online
ISSN
2191-0251
See all formats and pricing
More options …
Volume 29, Issue 1

Issues

Effects of methylphenidate on appetite and growth in children diagnosed with attention deficit and hyperactivity disorder

Fatih Gurbuz / Berrak Bilginer Gurbuz / Gonca Gul Celik / Veli Yildirim / Seyit Ahmet Ucakturk
  • Ankara Pediatric Hematology Oncology Training and Research Hospital, Pediatric Endocrinology, Ankara, Turkey
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Gulsah Seydaoglu / Eda Mengen UcakturkORCID iD: http://orcid.org/0000-0003-1597-8418 / Ali Kemal Topaloglu / Bilgin Yuksel
Published Online: 2015-08-15 | DOI: https://doi.org/10.1515/jpem-2015-0171

Abstract

The purpose of this study was to determine the levels of leptin, ghrelin, and nesfatin-1 to elucidate the causes of poor appetite and growth retardation in patients receiving methylphenidate therapy for attention deficit hyperactivity disorder. The study was performed on 89 male subjects; 48 patients and 41 healthy controls, aged 7–14 years. Following treatment, patients’ leptin levels increased and ghrelin levels decreased while no significant change was found in nesfatin-1 levels. Of the 48 patients, 34 developed lack of appetite. In patients who developed lack of appetite, body weight SDS, body mass index (BMI), and BMI SDS were statistically significantly reduced; moreover, height SDS was reduced, though not to a statistically significant extent. This study attempted to elucidate the mechanisms that mediate the association between methylphenidate and appetite and growth, for which no studies have yet to be published.

Keywords: appetite; attention deficit and hyperactivity; ghrelin; growth; leptin; methylphenidate; nesfatin-1

References

  • 1.

    Arora S, Anubhuti. Role of neuropeptides in appetite regulation and obesity–a review. Neuropeptides 2006;40:375–401.CrossrefGoogle Scholar

  • 2.

    Keen-Rhinehart E, Ondek K, Schneidr JE. Neuroendocrine regulation of appetitive ingestive behavior. Front Neurosci 2013;7:213.Google Scholar

  • 3.

    Sobrino Crespo C, Perianes Cachero A, Puebla Jiménez L, Barrios V, Arilla Ferreiro E. Peptides and food intake. Front Endocrinol (Lausanne) 2014;5:58.CrossrefGoogle Scholar

  • 4.

    Anık A, Çatlı G, Abacı A, Küme T, Bober E. Fasting and postprandial levels of a novel anorexigenic peptide nesfatin in childhood obesity. J Pediatr Endocrinol Metab 2014;27:623–8.Web of ScienceGoogle Scholar

  • 5.

    Vehapoglu A, Ustabas F, Ozgen TI, Terzioglu S, Cermik BB, et al. Role of circulating adipocytokines vaspin, apelin, and visfatin in the loss of appetite in underweight children: a pilot trial. J Pediatr Endocrinol Metab 2015;28:1065–71.Web of ScienceGoogle Scholar

  • 6.

    Kitahara CM, Trabert B, Katki HA, Chaturvedi AK, Kemp TJ, et al. Body mass index, physical activity, and serum markers of inflammation, immunity, and insulin resistance. Cancer Epidemiol Biomarkers Prev 2014;23:2840–9.Web of ScienceCrossrefGoogle Scholar

  • 7.

    Olama SM, Elsaid TO, El-Arman M. Serum leptin in Egyptian patients with fibromyalgia syndrome: relation to disease severity. Int J Rheum Dis 2013;16:583–9.Web of ScienceCrossrefGoogle Scholar

  • 8.

    Wang Y, Shen Y, Zuo Q, Zhao L, Wan C, et al. Evaluation of ghrelin level and appetite regulation in patients with acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2014;9:863–70.Google Scholar

  • 9.

    Kanat BH, Ayten R, Aydın S, Girgin M, Cetinkaya Z, et al. Significance of appetite hormone ghrelin and obestatin levels in the assessment of the severity of acute pancreatitis. Turk J Gastroenterol 2014;25:309–13.CrossrefWeb of ScienceGoogle Scholar

  • 10.

    Zabarovskaja S, Freda P, Williams JJ, Kunavarapu C, Lamanca J, et al. Acylation of ghrelin is increased in heart failure and decreases post heart transplantation. Scand Cardiovasc J 2014;48:343–8.Web of ScienceGoogle Scholar

  • 11.

    Naufel MF, Bordon M, de Aquino TM, Ribeiro EB, de Abreu Carvalhaes JT. Plasma levels of acylated and total ghrelin in pediatric patients with chronic kidney disease. Pediatr Nephrol 2010;25:2477–82.CrossrefWeb of ScienceGoogle Scholar

  • 12.

    Baratta M. Leptin–from a signal of adiposity to a hormonal mediator in peripheral tissues. Med Sci Monit 2002;8:282–92.Google Scholar

  • 13.

    Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998;395:763–70.Google Scholar

  • 14.

    Wauters M, Considine RV, Van Gaal LF. Human leptin: from an adipocyte hormone to an endocrine mediator. Eur J Endocrinol 2000;143:293–311.Google Scholar

  • 15.

    Webber J. Energy balance in obesity. Proc Nutr Soc 2003;62:539–43.CrossrefGoogle Scholar

  • 16.

    Harvey J. Leptin regulation of neuronal morphology and hippocampal synaptic function. Front Synaptic Neurosci 2013;5:3.Google Scholar

  • 17.

    Büyükgebiz B, Oztürk Y, Yilmaz S, Arslan N. Serum leptin concentrations in children with mild protein-energy malnutrition and catch-up growth. Pediatr Int 2004;46:534–538.CrossrefGoogle Scholar

  • 18.

    Trayhurn P, Hoggard N, Mercer JG, Rayner DV. Leptin: fundamental aspects. Int J Obes Relat Metab Disord 1999;23:22–28.Google Scholar

  • 19.

    Salman N, Ozturk G, Akin I, Kilicaslan S, Demirel F, et al. The effect of adenotonsilectomy on ghrelin, leptin, IGF-1 levels and growth parameters in children with adenotonsillar hypertrophy. J Pediatr Endocrinol Metab 2014;27:885–90.CrossrefWeb of ScienceGoogle Scholar

  • 20.

    Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656–60.Google Scholar

  • 21.

    Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB. Ghrelin–a hormone with multiple functions. Front Neuroendocrinol 2004;25:27–68.Google Scholar

  • 22.

    Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, et al. A role for ghrelin in the central regulation of feeding. Nature 2001;409:194–8.Google Scholar

  • 23.

    Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 2001;86:4753–8.Google Scholar

  • 24.

    Toshinai K, Date Y, Murakami N, Shimada M, Mondal MS, et al. Ghrelin-induced food intake is mediated via the orexin pathway. Endocrinology 2003;144:1506–12.Google Scholar

  • 25.

    Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006;443:709–12.Google Scholar

  • 26.

    Shimizu H, Oh-I S, Hashimoto K, Nakata M, Yamamoto S, et al. Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-independent mechanism. Endocrinology 2009;150:662–71.Web of ScienceGoogle Scholar

  • 27.

    Shimizu H, Oh-I S, Okada S, Mori M. Nesfatin-1: an overview and future clinical application. Endocr J 2009;56:537–43.Web of ScienceGoogle Scholar

  • 28.

    American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorder, 4th ed. Washington, DC, American Psychiatric Association, 1994, 55–85.Google Scholar

  • 29.

    Didoni A, Sequi M, Panei P, Bonati M; Lombardy ADHD Registry Group. One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder. Eur J Clin Pharmacol 2011;67:1061–7.Google Scholar

  • 30.

    Mannuzza S, Klein RG, Bonagura N, Malloy P, Giampino TL, et al. Hyperactive boys almost grown up. V. Replication of psychiatric status. Arch Gen Psychiatry 1991;48:77–83.Google Scholar

  • 31.

    Günther T, Kahraman-Lanzerath B, Knospe EL, Herpertz-Dahlmann B, Konrad K. Modulation of attention-deficit/hyperactivity disorder symptoms by short- and long-acting methylphenidate over the course of a day. J Child Adolesc Psychopharmacol 2012;22:131–8.Web of ScienceGoogle Scholar

  • 32.

    Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 2004;113:206–16.Google Scholar

  • 33.

    Brams M, Mao AR, Doyle RL. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder. Postgrad Med 2008;120:69–88.Web of ScienceGoogle Scholar

  • 34.

    Aagaard L, Hansen EH. Adverse drug reaction labelling for atomoxetine, methylphenidate and modafinil: comparison of product information for oral formulations in Australia, Denmark and the United States. Curr Drug Saf 2013;8:162–8.Google Scholar

  • 35.

    Lee MS, Lee SI, Hong SD, Kim JH, Choi J, et al. Two different solicitation methods for obtaining information on adverse events associated with methylphenidate in adolescents: a 12-week multicenter, open-label study. J Child Adolesc Psychopharmacol 2013;23:22–7.Web of ScienceGoogle Scholar

  • 36.

    Findling RL, Wigal SB, Bukstein OG, Boellner SW, Abikoff HB, et al. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. Clin Ther 2009;31: 1844–55.Google Scholar

  • 37.

    Lee J, Grizenko N, Bhat V, Sengupta S, Polotskaia A, et al. Relation between therapeutic response and side effects induced by methylphenidate as observed by parents and teachers of children with ADHD. BMC Psychiatry 2011;11:70.CrossrefWeb of ScienceGoogle Scholar

  • 38.

    Neyzi O, Saka HN, Kurtoğlu S. Anthropometric studies on the Turkish population--a historical review. J Clin Res Pediatr Endocrinol 2013;5:1–12.Google Scholar

  • 39.

    Grimberg A, Lifshitz F. Worrisome Growth. In: Lifshitz F, editor. Pediatric Endocrinology.5th ed. New York: Informa Healthcare, 2007:1–50.Google Scholar

  • 40.

    Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, et al. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol 2006;13:50–62.Google Scholar

  • 41.

    McGough JJ, McBurnett K, Bukstein O, Wilens TE, Greenhill L, et al. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2006;16:351–6.Google Scholar

  • 42.

    Işeri E, Kiliç BG, Senol S, Karabacak NI. Effects of methylphenidate on leptin and appetite in children with attention-deficit hyperactivity disorder: an open label trial. Methods Find Exp Clin Pharmacol 2007;29:47–52.Web of ScienceGoogle Scholar

  • 43.

    Methylphenidate: growth retardation. Prescrire Int 2011;20:238–9.Google Scholar

  • 44.

    Zhang H, Du M, Zhuang S. Impact of long-term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics 2010;41:55–9.Web of ScienceGoogle Scholar

  • 45.

    Lisska MC, Rivkees SA. Daily methylphenidate use slows the growth of children: a community based study. J Pediatr Endocrinol Metab 2003;16:711–8.Google Scholar

About the article

Corresponding author: Fatih Gurbuz, MD, Number of ESPE Membership: 123115 Cukurova University Medical Faculty, Department of Pediatric Endocrinology, Adana 01330, Turkey, Tel: +90 322 3386060 /3252, Mobile phone: +09 505 7077366, Fax: +90 322 3387717, E-mail:


Received: 2015-04-22

Accepted: 2015-07-20

Published Online: 2015-08-15

Published in Print: 2016-01-01


Citation Information: Journal of Pediatric Endocrinology and Metabolism, Volume 29, Issue 1, Pages 85–92, ISSN (Online) 2191-0251, ISSN (Print) 0334-018X, DOI: https://doi.org/10.1515/jpem-2015-0171.

Export Citation

©2016 by De Gruyter.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Nancy Sturman, Laura Deckx, and Mieke L van Driel
Cochrane Database of Systematic Reviews, 2017
[2]
R. Bou Khalil, N. Fares, Y. Saliba, J. Tamraz, and S. Richa
L'Encéphale, 2017
[3]
Roberta Sellaro and Lorenza S. Colzato
Appetite, 2017, Volume 113, Page 301
[4]
Doerte Hilgard, Katja Konrad, Michael Meusers, Bela Bartus, Klaus-Peter Otto, Rudolf Lepler, Edith Schober, Esther Bollow, and Reinhard W. Holl
Pediatric Diabetes, 2016

Comments (0)

Please log in or register to comment.
Log in